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Intraglomerular coagulation is thought to be involved in the
development of glomerular injury [1, 2]. High levels of fibrin-
related antigen (FRA) are often present in injured glomeruli,
and cross linked FRA (XL-FRA) also occurs in the endothelium
of these glomeruli [3). XL-FRA is currently detected using the
monoclonal antibody DD3B6/22 against the d-dimer. However,
XL-FRA staining is usually weaker than that of FRA. We used
plasmin to detect the antigemcity of the d-dimer in the glomer-
ulus. After this procedure, FRA staining was virtually un-
changed and XL-FRA staining often increased. Sometimes,
XL-FRA staining was negative before, and apparently positive
after, plasmin treatment. This method is useful for detecting the
intraglomerular deposition of cross linked fibrin (XFb).
Methods
Patients
Nineteen patients with various glomerular diseases were
studied. Fifteen had IgA nephropathy (IgAN), 2 had Henoch-
SchOnlein purpura nephritis (HSPN), 1 had type I membrano-
proliferative glomerulonephritis, and 1 had Wegener's granulo-
matosis (WG). The diagnosis was confirmed by renal biopsy
after light microscopy, immunofluorescence microscopy, and
electron microscopy, as well as clinical findings.
Preparation offibrinogen and XFb
Fibrinogen was isolated with nitroblue tetrazolium [4]. XFb
was prepared by incubating one volume of fibrinogen (2.5
mg/mI) in 0.018 si phosphate buffer (pH 7.8), with I unit of
factor XIII (Calbiochem, San Diego, California, USA) per
volume, 5 units of thrombin (Green Cross, Osaka, Japan) per
volume, one volume of 0.075 M CaCl2, and one volume of 0.035
M L-cysteine. The incubation proceeded for three hours at
37°C. After centrifugation, XFb clots were obtained. The XFb
clots were produced two times independently.
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Plasmin treatment
All biopsy specimens were frozen in OCT compound and
sectioned successively on a cryostat. The active form plasmin
(Green Cross, Osaka, Japan) was prepared at a concentration of
0.25 casein U/mi in 0.01 M phosphate buffer saline (pH 7.4).
Sections were attached onto the albumin-coated slides, incu-
bated with plasmin for 10 minutes at room temperature, and
washed three times with PBS.
Immunoperoxidase staining for light microscopy (IPLM)
Cryostat sections were stained either directly [51 or indi-
rectly. FRA was directly detected before and after incubation
with plasmin using a monospecific goat antibody against human
fibrinogen (Cappel Laboratories, Cochranville, Pennsylvania,
USA). XL-FRA was indirectly detected before and after plas-
mm exposure by using the monoclonal antibody, DD3B6/22
(mouse IgU fraction, AGEN, Brisbane, Australia) [6]. A mono-
clonal antibody against human a2-plasmin inhibitor (a2-PI)
(Teijin Diagnostics, Osaka, Japan) was used to directly detect
a2-PI before plasmin incubation. Direct staining was performed
as follows. Sections were first incubated with horseradish-
peroxidase (HRPO)-labeled IgG-Fab fragments against human
fibrinogen or HRPO-labeled IgG fraction against human a2-PI.
Color was then developed by incubation with 3,3'-diaminoben-
zidine in 0.01% H202. For indirect staining, sections were
incubated with mouse monoclonal antibody, followed by bio-
tinylated anti-mouse IgG. Sections were then reacted with
HRPO-labeled avidin and color was developed as described
above. All sections were post-stained with PAS. The intensity
of the staining before and after plasmin incubation was com-
pared.
Immunoelectron microscopy (JEM)
Portions of the biopsy specimens were fixed in periodate-
lysine-paraformaldehyde according to the method of Mclean
and Nakane [7]. The subsequent procedures were as described
previously [8, 91. In brief, specimens were washed with various
concentrations of sucrose, frozen in OCT compound, and
sectioned (8 m) on a cryostat. Sections were reacted with
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Fig. 1. Reactivity of the monoclonal antibody
DD3B6/22 to XFb and fibrinogen before and
after plasmin treatment. The reaction color in
plasmin-untreated XFb section was negative
by immunofluorescence microscopy (A), and
by immunoperoxidase staining (C). After
plasmin exposure, the reaction color became
positive (B, D), respectively. Both reaction
colors in the slides of plasmin-untreated (E)
and -treated fibrinogen (F) were negative. x
300. XFb, cross linked fibrin.
then stained with 3,3'-diaminobenzidine. Sections were post-
fixed in 2% osmic acid, embedded in Epon 812, and ultrathin
sections were prepared.
Reactivity of the antisera
The reactivity of the monoclonal antibody DD3B6/22 was
tested on both sections of plasmin-treated and -untreated XFb
clots. The reactivity of the monoclonal antibody DD3B6/22 was
tested as follows. Two independently-produced XFb clots were
sectioned and attached onto the albumin-coated slides. A total
of seven pairs of slides were evaluated. The fibrinogen solution
was also dried on the coated slides. These slides of XFb and
fibrinogen were stained by immunofluorescence microscopy
(IFM) or IPLM using DD3B6/22 before and after plasmin
treatment. In indirect staining for IFM, fluorescein-conjugated
avidin was used instead of HRPO-labeled avidin for IPLM.
Statistical methods
The intensities of the FRA and XL-FRA staining were
compared before and after plasmin treatment by the indepen-
dent judgment of at least two investigators. Differences be-
tween groups were analyzed by the chi-square test. Statistical
significance was set at P <0.05.







Increased Unchanged Decreased Total
FRA fibrinogen 2 16 1 19
XLFRAa d-dimer 9 10 0 19
Abbreviations are: FRA, fibnn-related antigen; XL-FRA, cross
linked FRA.
a Different from XL-FRA and FRA at P < 0.05.
Results
The reaction color in plasmin-untreated XFb sections was
faint using the monoclonal antibody DD3B6122. In contrast, an
intense reaction color was observed in the plasmin-treated
sections of XFb clots using the same antibody both by the IFM
and IPLM study (Fig. 1). The change of the color from faint to
intense staining after plasmin treatment was observed in all
seven pairs of slides. The reaction color in both slides of
plasmin-treated and -untreated fibrinogen was also faint when
using the same monoclonal antibody.
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Fig. 2. Reactivity of a monospecfic goal antibody against fibrinogen in a glomerulus sample from Henoch-Schönlein purpura nephritis. The
staining intensity was not changed before (A), or after (B) plasmin treatment. x 350.
the monoclonal antibody DD3B6/22 increased after plasmin
treatment, whereas in the remaining 10, the staining was
unchanged (Table 1). FRA staining using the antibody against
fibrinogen did not affect the color after plasmin treatment in
most samples. In all specimens before and after plasmin expo-
sure, the XL-FRA staining was equal to or weaker than that of
FRA. At no time was FRA negative while XL-FRA was
positive after plasmin treatment. The change in staining inten-
sity after plasmin treatment was significantly different between
in FRA and XL-FRA (P < 0.05).
Figures 2 and 3 show typical FRA and XL-FRA staining in
HSPN, in which FRA staining was not affected by plasmin,
whereas XL-FRA staining became intense both in the me-
sangium and along the capillary loops. In plasmin-untreated
sections, the XL-FRA staining was faint, and the reaction color
became apparently positive after plasmin treatment.
Among 15 IgA-N specimens, six showed the increasing
intensity of XL-FRA staining after plasmin treatment, and nine
showed no change of staining intensity. On the other hand, both
of the HSPN specimens showed an apparent increasing change
of XL-FRA staining after plasmin exposure.
By IEM, XL-FRA was also seen to react weakly before and
intensely after plasmin treatment both in the mesangium and
endothelium (Fig. 4).
In the patient with WG, severe cellular crescents were
involved (Fig. 5A). Intense XL-FRA staining was observed in
the crescents both before and after plasmin treatment (Fig. 5B).
The deposition of a2-PI was studied in 17 out of 19 total
specimens before plasmin treatment. Among specimens in
which FRA and XL-FRA were intensely stained before and/or
after plasmin exposure, a2-PI was positive. However, there was
no correlation between a2-PI deposition and conversion of the
XL-FRA staining after plasmin treatment.
Discussion
It is generally accepted that intraglomerular coagulation and
inhibition of fibrinolysis play a role in the progression of
glomerular injury. Various coagulation-fibrinolysis and platelet
membrane antigens have been observed by immunofluorescent
microscopy [10—14]. As an inhibitor of plasmin activities, a2-PI
has also been found in glomeruli [15]. By IPLM and IEM, we
reported that intraglomerular coagulation and platelet aggrega-
tion play a role in the progression of glomerular injury [3].
In the present study we used IFM and IPLM to test the
reactivity of the monoclonal antibody DD3B6/22 using the
sections of XFb clots produced in vitro. To observe the
localization of the antigenicity in detail against a clear morpho-
logical background in biopsy specimens, we mainly used IPLM
and IEM instead of IFM. IFM detected the existence of the
antigenicity in the biopsy specimens, and was not concerned
with precise localization (data not shown).
D-dimers result from plasmic cleavage of XFb only, and
plasmic derivatives of fibrinogen and non-XFb do not contain
d-dimer fragments [16]. Therefore, plasmic derivatives which
do not contain the d-dimer are not derived from XFb, but are
degradation products of fibnnogen or non-XFb.
The monoclonal antibody DD3B6/22 has been described to
react intensely with the late degradation products of XFb and
purified d-dimer, but not with fibrinogen or its degradation
products [6, 13]. We have also reported that, using purified
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Fig. 3. Reactivity of the monoclonal antibody DD3B6/22 to the same glomerulus as shown in Figure 2. Using successive sections of the same
glomerulus, the reaction color was faint before plasmin treatment (A). After plasmin treatment, the reaction color was intensely positive both in
the mesangium and along the capillary loops (B). x 350.
Fig. 4. Reactivity of the monoclonal antibody DD3B6/22 to a glomerulus in igA nephropathy by immunoelectron microscopy. There was weak
staining in the mesangial electron-dense deposits (arrow) before plasmin treatment (A), which became intense thereafter both in the mesangium
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Fig. 5. Light microscopic and immunoperoxidase staining findings in a patient with Wegener's granulomatosis. (A) A large crescent in the urinary
space with marked cell infiltration and collapse of the glomerular tuft (large arrow), and an intact glomerulus (small arrow). PAS stain. X 200. (B)
Extensive deposits of XL-FRA in the urinary space (large arrow), and an intact glomerulus (small arrow). Immunoperoxidase staining after plasmin
treatment. x 200. XL-FRA, cross linked fibrin-related antigen.
d-dimer by HPLC gel filtration, the reactivity of the antibody
DD3B6/22 to d-dimer was confirmed by a dot-immunobinding
assay [3].
In this study, using the mouse monoclonal antibody
DD3B6/22 and sections of XFb clots synthesized in vitro,
samples which were faintly stained before piasmin treatment
became intensely colored thereafter. Therefore, we suspected
that the materials in the renal biopsy specimens which are
detected using DD3B6/22 are not intact XFb, but are XFb
fragments resulting from plasmin attack or degradation prod-
ucts. We therefore used the nomenclature XL-FRA, not XFb,
for products that were detected by the antibody DD3B6/22
against d-dimer in biopsy specimens before plasmin treatment.
We suggest that in renal biopsy specimens, if plasmin treatment
is not performed XFb may not be detected sufficiently.
We used various concentration of plasmin, and various
incubation periods (data not shown). At a concentration higher
than 0.25 casein U/mi, or incubation period longer than 10
minutes, the specimens were too severely damaged, and at a
lower concentration and shorter incubation period, the effect of
plasmin treatment was inefficient.
When XL-FRA staining was intense before plasmin treat-
ment, we concluded that XFb was attacked by plasmin in vivo,
and that sufficient fibrinolysis had occurred after coagulation
with the cross linking of fibrinogen. The change in staining after
plasmin treatment significantly differed in FRA and XL-FRA
(P < 0.05). When XL-FRA staining was faint before plasmin
treatment, then became positive, coagulation probably oc-
curred with poor plasmin activity in vivo.
Six out of 15 IgAN specimens (40%) showed the increasing
intensity of XL-FRA staining after plasmin treatment. In con-
trast, both of the HSPN specimens showed apparent increasing
change in the same procedure. In this context, HSPN FRA is
regularly found in the glomeruli [17]. In the glomeruli of HSPN,
coagulation may progress with relatively low plasmin activity as
compared with the glomeruli of IgAN. An extended study with
HSPN is required to test this hypothesis.
An increased FRA staining intensity was observed with the
antibody against fibrinogen by piasmin treatment in two patient
specimens and decreased staining intensity in one specimen.
The cause of increased FRA staining in the two specimens
might be the general effect of unmasking. On the other hand, in
one specimen with decreased staining intensity FRA may have
been washed away during the plasmin treatment when the
quantity of FRA was relatively small. In 16 out of a total of 19
specimens plasmin treatment did not affect the color of FRA
staining. Therefore, FRA staining intensity virtually does not
change after plasmin treatment.
Some authors have reported that the monoclonal antibody
DD3B6/22 does not bind to crescents in human glomerulone-
phritis, and suggested that the FRA deposited in the crescents
was fibrinogen or its degradation products, and not fibrin [18].
However, we observed intense staining in severe crescents in
WG both before and after plasmin treatment. In acute and
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severe crescents XL-FRA may be present. In another patient
that we tested, there was no FRAand/orXL-FRA deposition in
the crescents. Further study of various kinds of glomerulone-
phritis is required to determine whether the conversion to
positive XL-FRA staining after plasmin treatment occurs in
crescents with intense FRA deposition.
In this study, none of the values of the fibrin/fibrinogen
degradation products (FDP) in the serum and urine samples
were markedly elevated, so far as was examined (data not
shown). One reason for this may be the low sensitivity to detect
FDP in the serum and urine. Further studies on the serum and
urine levels of FDP with elevated measurement sensitivity are
required to determine the relationship of the change of XL-FRA
staining after plasmin treatment.
In conclusion, plasmin exposure and use of the antibody
DD3B6/22 together provide a sensitive and convenient method
with which to determine intrinsic plasmin activity in renal
biopsy specimens in situ, and to evaluate the participation of
coagulation-fibrinolysis.
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